Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiprodil in TSC or FCD Type II
NCT06392009Phase 2Active, not recruiting
- Sponsor
- GRIN Therapeutics, Inc.
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of radiprodil in tuberous sclerosis complex (TSC) and focal cortical dysplasia type II (FCD-II) (2 arms), sponsored by GRIN Therapeutics, Inc. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 1.5 years, Maximum plasma concentration at 25 weeks and 4 more. Started Jul 2024; status: active, not recruiting.
02
Drugs
radiprodil
03
Conditions
tuberous sclerosis complex (TSC)focal cortical dysplasia type II (FCD-II)
Beyond the preview
Go deeper on NCT06392009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06392009.